Ozempic is already used for weight loss. Could it fight addiction too?

Listen & Subscribe

Choose your preferred player:

For questions about subscriptions or your Slate Plus feed, check our FAQ.

Get Your Slate Plus Podcast

If you can’t access your feeds, please contact customer support.

Thanks! Check your phone for a link to finish setting up your feed.

Please enter a 10-digit phone number.

Listen on your phone:RECOMMENDED

Enter your phone number and we’ll text you a link to set up the
podcast in your app:

Text me the link!

We’ll only text you about setting up this podcast, no spam.

Listen on your computer:

Apple Podcasts will only work on MacOS operating systems since Catalina. We do not support Android apps on desktop at this time.

Listen on your device:RECOMMENDED

These links will only work if you’re on the device you listen to podcasts on. We do not support Stitcher at this time.

We are showing you options for a computer but if you’re on a phone or tablet
We are showing you options for a phone or a tablet but if you’re on a computer,
click here. If you still have questions about subscriptions or your Slate Plus Feed, check our FAQ.

We’re sorry, but something went wrong while fetching your podcast feeds. Please contact us at plus@slate.com for help.

Episode Notes

Semaglutide, otherwise known as Ozempic, has been making headlines as a weight loss drug – despite only having FDA approval to treat diabetes. Now, some say it doesn’t just quell cravings for food – it helps quiet cravings for alcohol, drugs, and other compulsive behaviors. For years, researchers have been studying Ozempic’s effectiveness as an addiction cure in animals. What have they found? And – does it actually work?

Guest: Sarah Zhang covers health and medicine for The Atlantic

If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Amicus—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work.

Podcast production by Evan Campbell.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source